With Claimed Designated Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/452)
  • Patent number: 11555186
    Abstract: A water-soluble prolamin composition, such as a zein composition, and methods for producing the same. A method for tagging items comprising applying a plurality of non-coding DNA tags in a prolamin composition, such as a zein composition, wherein the selection of the particular taggants corresponds with a binary or nonbinary code sequence containing information about the tagged items.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: January 17, 2023
    Assignee: Safetraces, Inc.
    Inventor: Peter Mattei
  • Patent number: 11547689
    Abstract: A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor where the composition is continuously administrated.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 10, 2023
    Assignee: Intrance International AB
    Inventor: Roger Bolsöy
  • Patent number: 11517536
    Abstract: The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 6, 2022
    Assignee: Synthon B.V.
    Inventors: Sonia Garcia Jimenez, Luis Nogueiras Nieto, Lisardo Alvarez Fernandez, Jose Velada Calzada
  • Patent number: 11484541
    Abstract: Nutraceutical composition for the activation of sirtuins in humans, the composition including from 10% by weight to 15% by weight of honokiol; from 12% by weight to 40% by weight of pterostilbene; from 22% by weight to 32% by weight of polydatin; from 25% by weight to 40% by weight of ellagic acid and from 1.5% by weight to 3% by weight of a mixture of zinc, seleniun, chromium and nicotinamide, the composition promoting the inhibition of cell degradation and aging phenomena.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: November 1, 2022
    Assignee: SIRTLIFE CORP.
    Inventors: Giovanni Ciallella, Lyudmyla Zaporozhets
  • Patent number: 11439614
    Abstract: Novel methods for isolating fish roe/egg extracts, notably a coagulum and a sediment extract, enriched in phospholipids and omega-3 fatty acids are described. Novel compositions comprising omega-3 polyunsaturated fatty acids and micronutrients, which may be used for the management of neurological conditions such as ADD-ADHD, autism, cognitive impairment, and mood disorders are also described. These compositions are homogenous compositions comprising effective amounts of omega-3 fatty acids in microencapsulated or emulsified form, and/or from the sediment extract from fish roe/egg, vitamin B6, magnesium, zinc and copper, and may further comprise additional ingredients such as folic acid (e.g., L-methyl folate) and gamma-linolenic acid (GLA).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 13, 2022
    Inventors: Adrien Beaudoin, Luc Beaudoin
  • Patent number: 11440975
    Abstract: The invention relates a process for preparing a cross-linked starch-based polymer comprising the following steps: 1) dissolving a starchy material in a suitable solvent to form a starchy material solution; and 2) adding a episulfide of formula (I), wherein R1, R2, R3 and R4 are independently selected from hydrogen and (C1-C3)alkyl in the starchy material solution in order to obtain the disulfide crosslinked starch-based polymer. In another aspect the invention concerns a disulfide-cross-linked starch-based polymer obtainable by the process of the invention, that is characterized by only disulfide bridges.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 13, 2022
    Assignee: ROQUETTE FRERES
    Inventors: Francesco Trotta, Fabrizio Caldera
  • Patent number: 11433024
    Abstract: A liquid oral pharmaceutical dosage form, comprising pharmacologically effective amounts of at least one histamine H2-receptor antagonist in a hydrophobic/lipophilic liquid substantially free from water comprising at least one viscosity enhancing agent, and pharmacologically effective amounts of one or more antacid(s) in a liquid comprising at least one viscosity enhancing agent and at least one flavor, wherein the two liquids are physically separated from each other and wherein the two liquids have matching rheological profiles and a package comprising multiple liquid oral dosage forms as well as a method of treating a gastric disease or disorder by use of the liquid oral pharmaceutical dosage form.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: September 6, 2022
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Salih Muhsin Muhammed, Katarina Lindell, Jill Nilgard, Sofi Nöjd
  • Patent number: 11341341
    Abstract: A conveyer mechanism (110) may include one or more composition inspection units provided along the intended product transport path. The product's composition, e.g., it's ink composition, is compared with a predetermined standard, to determine whether the product is acceptable. A bar code (48, 45.1, 47.1, 85) may be provided to an external surface of the article for identification/traceability purposes.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 24, 2022
    Assignee: Ackley Machine Corporation
    Inventors: E. Michael Ackley, Daniel J. Palmer
  • Patent number: 11324702
    Abstract: The present disclosure generally relates to film-forming compositions and capsules formed from such compositions, including processes for using such compositions to make capsules. In some embodiments, the film-forming compositions are free of animal products and carrageenan.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 10, 2022
    Assignee: Captek Softgel International, Inc.
    Inventors: Ronnie E. Bayless, Timothy Brian Chiprich
  • Patent number: 11311516
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: April 26, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11304937
    Abstract: The present invention provides a particle comprising pirfenidone and a lipid, particularly magnesium stearate, and having a mean particle diameter of 5 ?m or less, and a powder formulation comprising the particle and a carrier.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: April 19, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takeshi Funaki, Yukiko Nishino, Yuki Masuda, Koichi Tsubone
  • Patent number: 11285107
    Abstract: The present invention relates to a process for manufacturing porous silica particles comprising at least one bioactive compound, whereby the particles are adapted for lung, nasal, sublingual and/or pharyngeal delivery of said at least one bioactive compound and have an MMAD between 0.5 and 15 ?m with a GSD less than 2.5. The invention also relates to a pharmaceutical composition comprising said silica particles and a use of the silica particles in the diagnoses, prevention and/or treatment of local and/or systemic disorders, such as disorders of the lung, nose, sublingual and/or pharynx.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 29, 2022
    Assignee: NANOLOGICA AB
    Inventors: Chunfang Zhou, Adam Feiler, Paulina Paszkiewicz, Xin Xia
  • Patent number: 11273169
    Abstract: The present invention provides a food that is effective for improving the intestinal environment by promoting proliferation of intestinal lactic acid bacteria and the like. The present invention provides a food that is effective for improving the intestinal environment, wherein the food includes (1) ?-polyglutamic acid or a composition containing ?-polyglutamic acid, and (2) oligosaccharide or a composition containing oligosaccharide.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: March 15, 2022
    Assignee: AJINOMOTO CO., INC.
    Inventors: Keishi Kameyama, Momoka Tsuneyoshi
  • Patent number: 11266605
    Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 8, 2022
    Assignee: TILLOTTS PHARMA AG
    Inventors: Roberto Carlos Bravo Gonzaléz, Felipe José Oliveira Varum, Thomas Buser
  • Patent number: 11241399
    Abstract: The present invention relates to a composition for stimulating muscle growth, repair and maintenance and the method of using the same. The present invention generally relates to compositions and methods for supporting muscle anabolism. The compositions described herein are pharmaceutical or nutritional compositions suitable for preserving muscle mass, strength, and/or function in a subject in need thereof. The compositions are based on a specially formulated mixture of essential amino acids (EAAs) and protein with additional components. Use of the compositions herein may prevent muscle atrophy associated with periods of rest, such as those following surgery, injury, inactivity and during recovery from disease.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 8, 2022
    Assignee: The Amino Company LLC
    Inventors: Robert Reese Wolfe, Frederick Lee Wolfe
  • Patent number: 11229612
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 25, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Patent number: 11219228
    Abstract: Provided is a liquid system comprising a first component and a second component the components selected from the group consisting of carbohydrates, sugar alcohols, food grade acids, food grade non-aqueous solvents and food grade salts wherein: a. the second component is different than the first component; b. the system has a melting point lower than each of the components; and c. the liquid system comprises 7% or less water. The systems are useful for protecting an active ingredient in a food system wherein the ingredient is stable at room temperature and retains its sensory properties after being diluted into an aqueous beverage for example to form a flavored aqueous beverage.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 11, 2022
    Assignee: FIRMENICH SA
    Inventors: Ronald H. Skiff, Ernst L. Steinboeck, Jean-Francois Basset
  • Patent number: 11160792
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: November 2, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11135159
    Abstract: The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 5, 2021
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Tanju Nacak
  • Patent number: 11110067
    Abstract: Disclosed are microcapsules that include an inhibitor of the mammalian target of rapamycin (mTOR) within the microcapsules, and pharmaceutical compositions and kits that include the microcapsules. Also disclosed are methods for treating or preventing an age-related disease, condition, or disorder in a subject that involve administering to a subject a pharmaceutically effective amount of microcapsules that includes an inhibitor of mTOR within the microcapsules.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: September 7, 2021
    Assignees: The Board of Regents of the University of Texas System, Southwest Research Institute
    Inventors: Zelton Dave Sharp, John R. Strong, Veronica Galvan, Salvatore Oddo, Herbert G. Wheeler
  • Patent number: 11090291
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 17, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11052049
    Abstract: The present disclosure provides for a capsule dosage form of triamterene, the dosage form comprising: a) triamterene having a weight percentage in a range of 25-45% with respect to the total ingredients in the capsule dosage form; b) magnesium stearate having a weight percentage in a range of 1.5-13% with respect to the total ingredients in the capsule dosage form; and c) at least one diluent having a weight percentage in a range of 42-73.5% with respect to the total mixture/ingredients encapsulated in the capsule dosage form. The present disclosure also provides for a convenient process for preparation of the capsule dosage form.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: July 6, 2021
    Assignee: ATOZ PHARMACEUTICALS PVT LTD
    Inventors: Natarajan Venkatachalam, Olaganathan Arumugam
  • Patent number: 11033505
    Abstract: The present invention relates to an oral complex preparation comprising: a capsule containing a fat-soluble first drug; and a solid preparation containing a second drug, the solid preparation being embedded into the capsule and including an oil-proof material coating layer on the surface thereof The oral complex preparation of the present invention prepared by embedding the solid preparation including the oil-proof material coating layer on the surface thereof and containing the second drug into the capsule containing the fat-soluble first drug enables two types of drug ingredients to be simultaneously administered.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 15, 2021
    Assignees: Korea United Pharm, Inc., United Science R&D Center
    Inventors: Yun Woong Choi, Dae Chul Ha, In Ho Kwon, Byung Jin Kim, Hee Yong Song, Min-Seok Kwon, Byung Gu Min, Sang Min Cho, Jae Sang Jang
  • Patent number: 11027021
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm
  • Patent number: 11013748
    Abstract: Phase-inverted capsules of a prodrug of budesonide are provided for treatment of bowel diseases.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 25, 2021
    Assignee: UNIVERSITY OF NIZWA
    Inventors: Anil K. Philip, Betty Annie Samuel, Hamna Naseer Al Senani, Afaf Mohammed Weli, Ahmed-Sulaiman Fadhil Al Harrasi, Ahmed bin Khalfan Al Rawahi
  • Patent number: 11007179
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: May 18, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11001585
    Abstract: The present invention relates to crystalline forms of ibrutinib, designated as Form S1, Form S2, Form S3, Form S4, and an amorphous form, designated as Form A1, and processes for their preparation, pharmaceutical compositions comprising these forms, and their use for the treatment of Bruton's tyrosine kinase (BTK) mediated diseases.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: May 11, 2021
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Ramkinkar Santra, Bala Krishna Reddy Bhogala, Chandra Has Khanduri
  • Patent number: 10993933
    Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 4, 2021
    Assignee: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Margaretha Olthoff
  • Patent number: 10973769
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: April 13, 2021
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 10940127
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Io Therapeutics, Inc., The Johns Hopkins University
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Patent number: 10933020
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 2, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Patent number: 10925832
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: February 23, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Patent number: 10918685
    Abstract: A topical liniment composition that boost muscle relaxation, increase blood flow, and increase cutaneous delivery of herbal extract that contains polyphenols derived from red chili, black pepper, cinnamon, and turmeric includes a quantity of castor-mineral oil-camphor solution, a quantity of eucalyptus oil, a quantity of clove oil, a quantity of peppermint oil, a quantity of frankincense oil, a quantity of herbal extract concentrate solution, and a quantity of castor oil. Aforementioned ingredients are heterogeneously mixed with each other to formulate the topical liniment composition at standard temperature and pressure (STP). Additionally, a quantity of petroleum jelly and a quantity of beeswax can be heterogeneously mixed with the topical liniment composition to formulate the topical balm composition.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 16, 2021
    Inventor: Ravi Ramamoorthy Iyer
  • Patent number: 10898438
    Abstract: A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: January 26, 2021
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Laura Baruzzi, David Griffith Williams, Sr., Arianna Provenza, Rodrigo Fuscelli Pytel
  • Patent number: 10899849
    Abstract: A method for the production of empty pullulan capsules eliminate the need to dry pullulan solid product, thereby reducing the equipment cost and energy consumption. The pullulan raw material production can be linked directly with the capsule production to provide a unique approach for empty capsule formation. The purified pullulan fermentation fluid can be directly used in capsule preparation, thus removing the need for a melting process. On the one hand, the method may decrease material consumption, save the cost of equipment and labor, reduce production time and increase productivity. On the other hand, the method may reduce the fluctuating of raw material quality in the re-melting process and guarantee a more stable capsule production and quality.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: January 26, 2021
    Assignee: LEFAN CAPSULE INTERNATIONAL INC
    Inventors: Xianyu Yun, Sheng Wang, Zhongming Fang, Fei Wang, Peiyong Liu, Xiaosan Cao, Zhidong Lu
  • Patent number: 10865160
    Abstract: The present disclosure relates to a nutrient-containing porous biodegradable bead comprising the following components: an Aloe Vera and cellulose composite matrix containing a nutrient solution including, but not limited to, nitrogen, phosphorus, potassium, sodium alginate, and calcium chloride.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: December 15, 2020
    Inventors: Axel Garcia-Burgos, Yoliem S. Miranda-Alanon
  • Patent number: 10813887
    Abstract: The present disclosure provides an acid resistant capsule shell composition including pectin with a degree of esterification (DE) of about 15% to about 40%, and a degree of amidation (DA) of greater than 0% to about 25%; and a divalent cation. An acid resistant capsule shell and a method for manufacturing the acid resistant capsule shell are also provided in the present disclosure.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 27, 2020
    Assignee: DAH FENG CAPSULE INDUSTRY CO., LTD
    Inventors: Ruei-Jan Chang, Yi-Huei Lin, Pei-Hsuan Lee, Hsin-Yi Chao
  • Patent number: 10752589
    Abstract: The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula (I).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: August 25, 2020
    Assignee: SPHAERA PHARMA PVT. LTD.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Somdutta Sen
  • Patent number: 10736872
    Abstract: A pharmaceutical composition in a physiological dose for a mammal is used for reducing vascular calcification caused due to statin consumption. The composition contains mixture 1 and statin. The mixture 1 contains combination of the Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine. The mixture 1 can be used as a stand-alone product with or without statin.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: August 11, 2020
    Inventor: Matthias W Rath
  • Patent number: 10709668
    Abstract: The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an active ingredient and a diluent.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: July 14, 2020
    Assignee: CONFLUENCE PHARMACEUTICALS, LLC
    Inventors: Steven L. Johns, Kenneth G. Payie, Badrinath R. Doniparthi, Shivaraj B. Munianjanappa
  • Patent number: 10695305
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 30, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & CO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Patent number: 10695367
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10688058
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 23, 2020
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 10682322
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: June 16, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & GO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 10682376
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: June 16, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10610543
    Abstract: The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 7, 2020
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10603286
    Abstract: An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: March 31, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Hugues Straub, Stefaan Jaak Vanquickenborne
  • Patent number: 10596122
    Abstract: Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 24, 2020
    Assignee: Medical Research Council
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodriguez Faria, Laetitia Pele, Rachel Hewitt, Emma Thomas-McKay
  • Patent number: 10588864
    Abstract: Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal pH but can dissolve at pH>6. The core of a particulate can further comprise an excipient such as a diluent, a binder, a disintegrant, a lubricant, a glidant or a combination thereof. Particulates can comprise pharmaceutical compounds for treating colonic diseases such as C. difficile infection, ulcerative colitis, colon cancer, and Crohn's disease.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 17, 2020
    Assignee: Gateway Pharmaceuticals LLC
    Inventor: Lianli Li
  • Patent number: 10555940
    Abstract: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: February 11, 2020
    Inventor: Robert I. Henkin